Bansal Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 27 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 2.78 Cr
- Revenue Growth 127.92%
- Profit Growth -141.06%
- Ebitda -89.34%
- Net Worth -1.00%
- Total Assets -4.28%
About Bansal Pharma
Bansal Pharma Limited (BPL) is a Public Limited Indian Non-Government Company incorporated in India on 11 September 1997 and has a history of 27 years and four months. Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company has closed loans amounting to ₹2.78 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Company Details
-
Location
Thane, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24200MH1997PLC110599
-
Company No.
110599
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
11 Sep 1997
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Bansal Pharma?
Board Members (3)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Sajankumar Bajaj | Director | 01-Apr-1998 | Current |
Anil Jain | Director | 31-Jul-1999 | Current |
Dhananjay Sabaji | Director | 01-Apr-2005 | Current |
Financial Performance of Bansal Pharma.
Bansal Pharma Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 127.92% increase. The company also saw a substantial fall in profitability, with a 141.06% decrease in profit. The company's net worth dipped by a decrease of 1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
|
||||||
Revenue from Operations |
|
||||||
Total Assets |
|
||||||
Profit or Loss |
|
||||||
Net Worth |
|
||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Bansal Pharma?
In 2023, Bansal Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹27.83 M
Charges Breakdown by Lending Institutions
- Corporation Bank : 2.00 Cr
- The Saraswat Co-Operative Bank Ltd : 0.78 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
20 Feb 2004 | The Saraswat Co-Operative Bank Ltd | ₹7.50 M | Satisfied |
04 Nov 1999 | The Saraswat Co-Operative Bank Ltd | ₹0.33 M | Satisfied |
23 Aug 1999 | Corporation Bank | ₹1.00 Cr | Satisfied |
23 Aug 1999 | Corporation Bank | ₹1.00 Cr | Satisfied |
How Many Employees Work at Bansal Pharma?
Unlock and access historical data on people associated with Bansal Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bansal Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bansal Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.